Current trends in West Nile virus vaccine development

被引：45

作者：

Amanna, Ian J. ^{[1
]}

Slifka, Mark K. ^{[2
]}

机构：

[1] Najit Technol Inc, Beaverton, OR 97006 USA

[2] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Div Neurosci, Beaverton, OR 97006 USA

来源：

EXPERT REVIEW OF VACCINES | 2014年 / 13卷 / 05期

关键词：

West Nile virus; immunocompromised; antibody; flaviviruses; neurotropic; epidemiology; vaccination; immunity; INACTIVATED POLIOVIRUS VACCINATION; I CLINICAL-TRIAL; T-CELL RESPONSES; NEUTRALIZING ANTIBODY-RESPONSE; RECOMBINANT ENVELOPE PROTEIN; HUMAN MONOCLONAL-ANTIBODIES; AMINO-ACID SUBSTITUTION; VECTOR-BASED VACCINE; UNITED-STATES; DNA VACCINE;

D O I：

10.1586/14760584.2014.906309

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37088 reported cases of WNV and 1549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been eight clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.

引用

页码：589 / 608

页数：20

共 175 条

[91] A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial [J].

Martin, Julie E. ;

Pierson, Theodore C. ;

Hubka, Sarah ;

Rucker, Steve ;

Gordon, Ingelise J. ;

Enama, Mary E. ;

Andrews, Charla A. ;

Xu, Qing ;

Davis, Brent S. ;

Nason, Martha C. ;

Fay, Michael P. ;

Koup, Richard A. ;

Roederer, Mario ;

Bailer, Robert T. ;

Gomez, Phillip L. ;

Mascola, John R. ;

Chang, Gwong-Jen J. ;

Nabel, Gary J. ;

Graham, Barney S. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (12) :1732-1740

[92]

Martina BEE, 2010, CURR OPIN INVEST DR, V11, P139

[93] YELLOW-FEVER VACCINE - DIRECT CHALLENGE OF MONKEYS GIVEN GRADED DOSES OF 17D VACCINE [J].

MASON, RA ;

TAURASO, NM ;

SPERTZEL, RO ;

GINN, RK .

APPLIED MICROBIOLOGY, 1973, 25 (04) :539-544

[94] Phylogeography of West Nile Virus: from the Cradle of Evolution in Africa to Eurasia, Australia, and the Americas [J].

May, Fiona J. ;

Davis, C. Todd ;

Tesh, Robert B. ;

Barrett, Alan D. T. .

JOURNAL OF VIROLOGY, 2011, 85 (06) :2964-2974

[95] A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity [J].

McDonald, William F. ;

Huleatt, James W. ;

Foellmer, Harald G. ;

Hewitt, Duane ;

Tang, Jie ;

Desai, Priyanka ;

Price, Albert ;

Jacobs, Andrea ;

Takahashi, Virginia N. ;

Huang, Yan ;

Nakaar, Valerian ;

Alexopoulou, Lena ;

Fikrig, Erol ;

Powell, T. J. .

JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (11) :1607-1617

[96] Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines [J].

Miller, Joseph D. ;

van der Most, Robbert G. ;

Akondy, Rama S. ;

Glidewell, John T. ;

Albott, Sophia ;

Masopust, David ;

Murali-Krishna, Kaja ;

Mahar, Patryce L. ;

Edupuganti, Srilatha ;

Lalor, Susan ;

Germon, Stephanie ;

Del Rio, Carlos ;

Mulligan, Mark J. ;

Staprans, Silvija I. ;

Altman, John D. ;

Feinberg, Mark B. ;

Ahmed, Rafi .

IMMUNITY, 2008, 28 (05) :710-722

[97] Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain [J].

Minke, J. M. ;

Siger, L. ;

Cupillard, L. ;

Powers, B. ;

Bakonyi, T. ;

Boyum, S. ;

Nowotny, N. ;

Bowen, R. .

VACCINE, 2011, 29 (28) :4608-4612

[98] A live, attenuated recombinant West Nile virus vaccine [J].

Monath, TP ;

Liu, J ;

Kanesa-Thasan, N ;

Myers, GA ;

Nichols, R ;

Deary, A ;

McCarthy, K ;

Johnson, C ;

Ermak, T ;

Shin, S ;

Arroyo, J ;

Guirakhoo, F ;

Kennedy, JS ;

Ennis, FA ;

Green, S ;

Bedford, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (17) :6694-6699

[99] Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys [J].

Monath, TP ;

Levenbook, I ;

Soike, K ;

Zhang, ZX ;

Ratterree, M ;

Draper, K ;

Barrett, ADT ;

Nichols, R ;

Weltzin, R ;

Arroyo, J ;

Guirakhoo, F .

JOURNAL OF VIROLOGY, 2000, 74 (04) :1742-1751

[100] Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen [J].

Monath, TP ;

Guirakhoo, F ;

Nichols, R ;

Yoksan, S ;

Schrader, R ;

Murphy, C ;

Blum, P ;

Woodward, S ;

McCarthy, K ;

Mathis, D ;

Johnson, C ;

Bedford, P .

JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08) :1213-1230

← 5 6 7 8 9 10 11 12 13 14 →